Eslicarbazepine Acetate Global Patent Coverage & Expiry Overview

Track protection status across key markets to assess launch feasibility.

Start your free 7-Day Trial! Book a demo to explore our global patent data.

It is formulated by 7 pharmaceutical companies such as SUMITOMO PHARMA AM, DR REDDYS, HETERO LABS LTD V and others. It is marketed under 2 brand names, including APTIOM, ESLICARBAZEPINE ACETATE. Available in 4 different strengths, such as 200MG, 400MG, 600MG and others, and administered through 1 route including TABLET;ORAL.

Strategic Dashboard

info

insightsStrategic Insights

Sourcing & Feasibility

check_circle API availability: autorenew Loading API feasibility...

groups Licensing: 7 potential partners

calendar_todayUS Launch window: autorenew Loading launch window...

timeline Key Patent Barrier & Expiry Timeline

autorenew Loading patent barriers...

factoryGeneric Manufacturer Snapshot

autorenew Loading manufacturers...

gavelRisk & Opportunity Summary

dangerous Risk: autorenew Loading risk analysis...
watch_later Watch: autorenew Loading watch analysis...
rocket_launch Opportunity: autorenew Loading opportunity analysis...
flag
gavel
calendar_today
calendar_today

Access Global Patent Data

Stay ahead with worldwide patent expiry and latest updates.

✓ Comprehensive global patent expiry timelines
✓ Full patent family details and status updates
Unlock Global Patents

Orange Book Drug Approval Timeline

FDA approval history for this ingredient

NDA (New Drug Application) ANDA (Generic Application)

Access Global Exclusivity and Patent Expiry Extensions

Stay ahead with worldwide patent expiry insights, exclusivity data, and latest updates.

✓ Comprehensive global patent expiry timelines
✓ Full patent family details and status updates
✓ Latest exclusivity data and extensions
Unlock Global Access

US Orange Book Patents Expiration Timeline

Key expiration dates for US patents covering this ingredient

View Global Patents Expiration Timeline

Stay ahead with worldwide patent expiry insights, market data, and research updates.

✓ Comprehensive global patent expiry timelines
✓ Full patent family details and status updates
Unlock Global Patent Timeline

Orange Book Drug Strengths

Latest drug strengths approved by FDA

Strength Route of Administration Companies Latest Approval Date

Orange Book Patents

Patents approved by the FDA for the ingredient

Patent Number Publication Date Legal Status Patent Expiry Date
{"application_id":"89980","ingredient":"ESLICARBAZEPINE ACETATE","trade_name":"APTIOM","family_id":"4e7f4e8dffe7447aa673","publication_number":"US10695354B2","cleaned_patent_number":"10695354","drug_product_flag":"-","drug_substance_flag":"-","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2025-05-06","publication_date":"2020-06-30","legal_status":"Expired"} US10695354B2 30 Jun, 2020 Expired 06 May, 2025
{"application_id":"89972","ingredient":"ESLICARBAZEPINE ACETATE","trade_name":"APTIOM","family_id":"4e7f4e8dffe7447aa673","publication_number":"US10702536B2","cleaned_patent_number":"10702536","drug_product_flag":"-","drug_substance_flag":"-","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2025-05-06","publication_date":"2020-07-07","legal_status":"Expired"} US10702536B2 07 Jul, 2020 Expired 06 May, 2025
{"application_id":"89979","ingredient":"ESLICARBAZEPINE ACETATE","trade_name":"APTIOM","family_id":"4e7f4e8dffe7447aa673","publication_number":"US10675287B2","cleaned_patent_number":"10675287","drug_product_flag":"-","drug_substance_flag":"-","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2025-05-06","publication_date":"2020-06-09","legal_status":"Expired"} US10675287B2 09 Jun, 2020 Expired 06 May, 2025
{"application_id":"89981","ingredient":"ESLICARBAZEPINE ACETATE","trade_name":"APTIOM","family_id":"4e7f4e8dffe7447aa673","publication_number":"US11364247B2","cleaned_patent_number":"11364247","drug_product_flag":"-","drug_substance_flag":"-","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2025-05-06","publication_date":"2022-06-21","legal_status":"Expired"} US11364247B2 21 Jun, 2022 Expired 06 May, 2025
{"application_id":"90050","ingredient":"ESLICARBAZEPINE ACETATE","trade_name":"APTIOM","family_id":"af488457dca4456a9b7d","publication_number":"US9206135B2","cleaned_patent_number":"9206135","drug_product_flag":"-","drug_substance_flag":"Y","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2026-04-21","publication_date":"2015-12-08","legal_status":"Granted"} US9206135B2 Molecular 08 Dec, 2015 Granted 21 Apr, 2026
{"application_id":"90025","ingredient":"ESLICARBAZEPINE ACETATE","trade_name":"APTIOM","family_id":"af488457dca4456a9b7d","publication_number":"US9643929B2","cleaned_patent_number":"9643929","drug_product_flag":"Y","drug_substance_flag":"-","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2026-04-21","publication_date":"2017-05-09","legal_status":"Granted"} US9643929B2 Formulation 09 May, 2017 Granted 21 Apr, 2026
{"application_id":"89941","ingredient":"ESLICARBAZEPINE ACETATE","trade_name":"APTIOM","family_id":"6f46fb211ecf4dbd9711","publication_number":"US9763954B2","cleaned_patent_number":"9763954","drug_product_flag":"-","drug_substance_flag":"-","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2028-09-13","publication_date":"2017-09-19","legal_status":"Granted"} US9763954B2 19 Sep, 2017 Granted 13 Sep, 2028
{"application_id":"90019","ingredient":"ESLICARBAZEPINE ACETATE","trade_name":"APTIOM","family_id":"2f1f2234dfe9419fa376","publication_number":"US9566244B2","cleaned_patent_number":"9566244","drug_product_flag":"Y","drug_substance_flag":"-","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2028-10-23","publication_date":"2017-02-14","legal_status":"Granted"} US9566244B2 Formulation 14 Feb, 2017 Granted 23 Oct, 2028
{"application_id":"90020","ingredient":"ESLICARBAZEPINE ACETATE","trade_name":"APTIOM","family_id":"2f1f2234dfe9419fa376","publication_number":"US10912781B2","cleaned_patent_number":"10912781","drug_product_flag":"Y","drug_substance_flag":"-","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2028-10-23","publication_date":"2021-02-09","legal_status":"Granted"} US10912781B2 Formulation 09 Feb, 2021 Granted 23 Oct, 2028
{"application_id":"89988","ingredient":"ESLICARBAZEPINE ACETATE","trade_name":"APTIOM","family_id":"2f1f2234dfe9419fa376","publication_number":"US8372431B2","cleaned_patent_number":"8372431","drug_product_flag":"Y","drug_substance_flag":"-","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2030-04-17","publication_date":"2013-02-12","legal_status":"Granted"} US8372431B2 Formulation 12 Feb, 2013 Granted 17 Apr, 2030
{"application_id":"6625","ingredient":"ESLICARBAZEPINE ACETATE","trade_name":"APTIOM","family_id":"c628849efb95498c8222","publication_number":"US9750747B2","cleaned_patent_number":"9750747","drug_product_flag":"-","drug_substance_flag":"-","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2032-08-24","publication_date":"2017-09-05","legal_status":"Granted"} US9750747B2 05 Sep, 2017 Granted 24 Aug, 2032

Recent Clinical Trials

Latest clinical trials and research studies for this ingredient

NCT ID Title Status Phase Conditions Start Date Completion Date

API Suppliers/Manufacturer (Branded/Generic companies)

Manufacturing Locations

View Complete Supplier List

Unlock access to all suppliers of Eslicarbazepine Acetate

✓ Access a comprehensive list of global suppliers
✓ Get information on each supplier
Unlock Suppliers

Note: Patent expirations and exclusivity timelines are dynamic and may shift based on litigation, regulatory extensions, and maintenance filings. Regular monitoring is advised.

GreyB © 2025 Elixir. All rights reserved.